Results 141 to 150 of about 120,659,427 (243)

Single-device in-sensor computing for multi-channel multiply-accumulate operations. [PDF]

Nat Commun
Wang M, Yu H, Wang B, Xu Z, Cai Z, Huang C, Zhao N.   +6 more
europepmc   +1 more source

Hardware-Efficient Stochastic Binary CNN Architectures for Near-Sensor Computing. [PDF]

Front Neurosci, 2021
Parmar V, Penkovsky B, Querlioz D, Suri M.   +3 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Phase-independent wireless data aggregation via optical in-sensor computing. [PDF]

Nat Commun
Sun S, Lu Z, Wang Y, Liu Z, Mao Z, Shi Q, Wang F, Wang W, Jiang J, Lu B, He H, Pan X, Qian H, Ye Z.   +13 more
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

End-to-end all-optical in-sensor computing system using photonic integrated circuits. [PDF]

Sci Adv
Xiao Z, Ren Z, Zhuge Y, Zhang Z, Yang Y, Dong B, Lee C.   +6 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Metal Oxide Nano-Interface Boosting the Deep Ultraviolet Adjustable Noise-Filtering In-Sensor Computing. [PDF]

Adv Mater
Ju Z, Li P, Yuan J, Yu B, Han B, Chen Y, Ma J, Xu H, Liu Y, Samorì P.   +9 more
europepmc   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

From Device-Level Implementation to In-Sensor Computing in Memristive-Device-Based Biosensors: A Review. [PDF]

Biosensors (Basel)
Ryu H, Lee WC, Lee J.
europepmc   +1 more source